Literature DB >> 29345428

TRAF3 regulation of inhibitory signaling pathways in B and T lymphocytes by kinase and phosphatase localization.

Alicia M Wallis1, Gail A Bishop1,2,3,4.   

Abstract

This brief review presents current understanding of how the signaling adapter protein TRAF3 can both induce and block inhibitory signaling pathways in B and T lymphocytes, via association with kinases and phosphatases, and subsequent regulation of their localization within the cell. In B lymphocytes, signaling through the interleukin 6 receptor (IL-6R) induces association of TRAF3 with IL-6R-associated JAK1, to which TRAF3 recruits the phosphatase PTPN22 (protein tyrosine phosphatase number 22) to dephosphorylate JAK1 and STAT3, inhibiting IL-6R signaling. An important biological consequence of this inhibition is restraining the size of the plasma cell compartment, as their differentiation is IL-6 dependent. Similarly, in T lymphocytes, interleukin 2 receptor (IL-2R) signaling recruits TRAF3, which in turn recruits the phosphatase TCPTP (T cell protein tyrosine phosphatase) to dephosphorylate JAK3. The resulting inhibition of IL-2R signaling limits the IL-2-dependent size of the T regulatory cell (Treg) compartment. TRAF3 also inhibits type 1 IFN receptor (IFNαR) signaling to T cells by this mechanism, restraining expression of IFN-stimulated gene expression. In contrast, TRAF3 association with two inhibitors of TCR signaling, C-terminal Src kinase (Csk) and PTPN22, promotes their localization to the cytoplasm, away from the membrane TCR complex. TRAF3 thus enhances TCR signaling and downstream T cell activation. Implications are discussed for these regulatory roles of TRAF3 in lymphocytes, as well as potential future directions. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  B cell; T cell; TRAF; signal transduction

Year:  2018        PMID: 29345428     DOI: 10.1002/JLB.2MIR0817-339RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  The Chx10-Traf3 Knockout Mouse as a Viable Model to Study Neuronal Immune Regulation.

Authors:  Jami M Gurley; Grzegorz B Gmyrek; Elizabeth A Hargis; Gail A Bishop; Daniel J J Carr; Michael H Elliott
Journal:  Cells       Date:  2021-08-12       Impact factor: 7.666

Review 2.  CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.

Authors:  Juan M Zapata; Gema Perez-Chacon; Pablo Carr-Baena; Ivan Martinez-Forero; Arantza Azpilikueta; Itziar Otano; Ignacio Melero
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

3.  Hypothermic oxygenated perfusion inhibits HECTD3-mediated TRAF3 polyubiquitination to alleviate DCD liver ischemia-reperfusion injury.

Authors:  Shaojun Ye; Qifa Ye; Wei Zhou; Zibiao Zhong; Danni Lin; Zhongzhong Liu; Qiuyan Zhang; Haoyang Xia; Sheng Peng; Anxiong Liu; Zhongshan Lu; Yanfeng Wang
Journal:  Cell Death Dis       Date:  2021-02-24       Impact factor: 8.469

Review 4.  K63 ubiquitination in immune signaling.

Authors:  Charitha Madiraju; Jeffrey P Novack; John C Reed; Shu-Ichi Matsuzawa
Journal:  Trends Immunol       Date:  2022-01-13       Impact factor: 16.687

5.  SH3-domain mutations selectively disrupt Csk homodimerization or PTPN22 binding.

Authors:  Ben F Brian; Frances V Sjaastad; Tanya S Freedman
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

6.  TRAF3 in T Cells Restrains Negative Regulators of LAT to Promote TCR/CD28 Signaling.

Authors:  Tina Arkee; Bruce S Hostager; Jon C D Houtman; Gail A Bishop
Journal:  J Immunol       Date:  2021-06-18       Impact factor: 5.426

Review 7.  Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity.

Authors:  Poojitha Sitaram; Bradley Uyemura; Subramaniam Malarkannan; Matthew J Riese
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.